Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomona...
Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections Phase I II clinical trial
Sepsis is the major problem of large burn patients and a predominant cause of death. The burn wound pathology, combined to a global intensive use of antibiotics (ATB), put patients at high risk of suffering from multidrug resistan...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SaPhaDe
Know your enemy systematic discovery of Salmonella anti Pha...
246K€
Cerrado
PID2021-125801OB-I00
ESTUDIO DEL METABOLISMO DEL ADN Y LAS BIOPELICULAS POLIMICRO...
182K€
Cerrado
CNS2023-145519
Inmunidad, infección e inmunoterapia
200K€
Cerrado
RYC2019-028015-I
Phage discovery: Towards new therapies against multidrug-res...
309K€
Cerrado
PYANO
Retargeted Pyocins A novel tool for combating major food bo...
200K€
Cerrado
PID2020-117708GB-I00
CARACTERIZACION DE LOS MECANISMOS DE RESISTENCIA ADQUIRIDOS...
121K€
Cerrado
Información proyecto PHAGOBURN
Líder del proyecto
MINISTERE DES ARMEES
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Sepsis is the major problem of large burn patients and a predominant cause of death. The burn wound pathology, combined to a global intensive use of antibiotics (ATB), put patients at high risk of suffering from multidrug resistant (MDR) infections, notably carried out by the Gram-negative bacteria species: Pseudomonas aeruginosa or Escherichia coli. But the last Gram- ATB is more than 20 years old and impeded by spread out exponential resistance. New ATB with genuine mode of action to target current resistant types are out of scope. In this context, MDR Gram- infections are becoming orphan pathologies without treatment. Fighting MDR in burn trauma is becoming an urgent medical need through innovation.
PHAGOBURN is focused on a highly promising alternative to ATB: phage therapy. Bacteriophages are viruses that specifically infect and kill bacteria during their replicative cycle. The main objective of the project is to assess the safety, effectiveness and pharmacodynamics of two therapeutic phage cocktails to treat either E. coli or P. aeruginosa burn wound infections. To reach that goal, a combined Phase I/II multicentric clinical trial will be carried out in 3 EU countries (France, Belgium, Switzerland), by different hospital burn units. Prior to that, a GMP bioproduction process will be implemented to produce both drug products according to current EMA standards. Meanwhile, the production process and the trial results will provide basis for an optimization of current regulatory guidelines.
PHAGOBURN is coordinated by the French Ministry of Defence. The Consortium also includes the following partners: Pherecydes (French SME) and Clean Cells (French SME) for the GMP bioproduction of drug products, CHU Vaudois (CH) burn wards, as well as the Royal Military Academy of Belgium (Queen Astrid).